Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer

Paolo Bidoli, Simonetta C. Stani, Luigi Mariani, Daniela De Candis, Diego Cortinovis, Stefania Aglione, Nicoletta Zilembo, Luisa Toffolatti, Barbara Formisano, Emilio Bajetta

Research output: Contribution to journalArticle


Purpose: Oxaliplatin (OHP) is a new platinum antineoplastic, while gemcitabine (GEM) is one of the most active drugs against non-small cell carcinoma (NSCLC). The OHP/GEM combination is interesting because the drugs have different mechanisms of action and toxicity profiles. The primary endpoint of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of OHP/GEM combination in non-small cell carcinoma of the lung. Methods: Patients with relapsed NSCLC were treated with fixed dose i.v. GEM (1250mg/m2) on days 1 and 8; followed on day 1 by i.v. OHP over 3h, starting from 70mg/m2 with 20mg/m2 increments, up to 130mg/m2. We enrolled 19 patients with eastern cooperative oncology group (ECOG) status 0/1=13/6; male/female=13/6. All had received first-line and foursecond-line chemotherapy. Results: Four patients dropped out. At dose level 2, one patient died of pulmonary embolism; at level 3, two patients died of disease progression. One patient at level 3, refused to continue treatment after allergic reaction (high fever episode) during infusion of third cycle. Fifteen patients were evaluable for toxicity and response. According to a priori statistical considerations, three patients in each of the first three treatment levels and six in the last level were evaluable. No G3-4 toxicity was observed at levels 1 and 2. G3 neutropenia and anemia occurred in 8% of cycles at level 3. Six patients entered level 4 (OHP 130mg/m2) with 22 courses delivered: G3-4 neutropenia occurred in 9%, G1-2 thrombocytopenia in 18%; other toxicities were mainly limited to G1-2 flu-like syndrome in about one third of patients and G1-2 nausea and vomiting in 5% of courses. There was no myelo-DLT at the highest dose level. There was no neurotoxicity at any level. Treatment was delayed in 12% and dose reduced in 26% of courses. There were 2/15 PR. Conclusions: MTD was not reached. OHP and GEM can probably be administered safely at 130 and 1250mg/m2, respectively, as first-line therapy. The schedule is being used in a phase II trial.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalLung Cancer
Issue number2
Publication statusPublished - Feb 2004


  • Chemotherapy
  • Gemcitabine
  • Non-small cell lung cancer
  • Oxaliplatin
  • Phase I study

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this